financetom
Business
financetom
/
Business
/
ON Semiconductor Q2 Shows 'Muted' Sales Recovery, Auto Weakness; BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ON Semiconductor Q2 Shows 'Muted' Sales Recovery, Auto Weakness; BofA Says
Aug 5, 2025 8:50 AM

11:23 AM EDT, 08/05/2025 (MT Newswires) -- ON Semiconductor (ON) Q2 earnings showed a "muted" sales recovery, particularly in industrial sales and a continued weakness in the US and European auto markets, BofA Securities said in a report Tuesday.

The report noted that ON's Q2 earnings "painted a picture of muted sales recovery, including a miss in industrial sales and ongoing exits from non-core segments." The company also saw "continued weakness in US/European auto" and "limited/no [gross margin] recovery for several quarters," the report said.

BofA downgraded the company's stock to neutral from buy and lowered the price target to $56 from $70, the report said.

While the company "offers the most [earnings per share] leverage in the industry and is executing on an interesting data center opportunity," the "recovery timing and data center growth isn't likely to shine until 2H of next year leaving the stock potentially range-bound."

Analysts at BofA also highlighted positive aspects, including strong free cash flow and a "data center opportunity" where sales have "nearly doubled YoY in Q2." However, these are balanced by risks such as "uncertainty around tariffs and auto/EV production" and "slower GM recovery."

Price: 47.57, Change: -0.40, Percent Change: -0.84

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Elanco Animal Health Gets US FDA Approval for Credelio Quattro
Elanco Animal Health Gets US FDA Approval for Credelio Quattro
Oct 7, 2024
04:46 PM EDT, 10/07/2024 (MT Newswires) -- Elanco Animal Health ( ELAN ) said late Monday the US Food and Drug Administration has approved the company's Credelio Quattro canine oral parasiticide. This monthly chewable tablet for dogs eight weeks of age or older is expected to launch in Q1 of 2025, the company said. Shares of the company fell 1.9%...
MEDIROM Acquires Rehabilitation Facilities; Shares Jump After Hours
MEDIROM Acquires Rehabilitation Facilities; Shares Jump After Hours
Oct 7, 2024
04:39 PM EDT, 10/07/2024 (MT Newswires) -- MEDIROM Healthcare Technologies ( MRM ) said Monday its MEDIROM Rehab Solutions unit has acquired all of the cerebral infarction rehabilitation centers owned and operated by Y's in Japan. The acquisition marks its expansion into the rehabilitation industry, MEDIROM said. Terms of the acquisition weren't disclosed. Shares of MEDIROM were up more than...
Cal-Maine Foods Plans $40 Million Expansion of Cage-Free Production Facilities
Cal-Maine Foods Plans $40 Million Expansion of Cage-Free Production Facilities
Oct 7, 2024
04:48 PM EDT, 10/07/2024 (MT Newswires) -- Cal-Maine Foods ( CALM ) said Monday its board approved $40 million in new projects to expand its cage-free production facilities, including the addition of five new cage-free layer houses in Florida, Georgia, Utah and Texas. The company said it will fund the projects with cash on hand, sales of investment securities and...
Procept BioRobotics Gets FDA Approval to Start Study for Prostate Cancer
Procept BioRobotics Gets FDA Approval to Start Study for Prostate Cancer
Oct 7, 2024
04:33 PM EDT, 10/07/2024 (MT Newswires) -- Procept BioRobotics ( PRCT ) said Monday that it has received approval from the US Food and Drug Administration for an investigational device exemption clinical trial to compare Aquablation therapy with radical prostatectomy. The study will enroll up to 280 patients at up to 50 centers and follow them for 10 years, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved